-
151P Baseline circulating tumor DNA (ctDNA) biomarker analysis of patients with human epidermal growth factor receptor 2 (HER2)-overexpressing metastatic non–small cell lung cancer (NSCLC) treated with trastuzumab deruxtecan (T-DXd)
E.F. Smit, Enriqueta Felip, D. Uprety, Misako Nagasaka, Kazuhiko Nakagawa, Luis G Paz-Ares, +12 more
1citations -
1574P Trastuzumab deruxtecan versus ramucirumab and paclitaxel as second-line therapy for patients with her2-positive gastric or gastro-esophageal junction adenocarcinoma: A propensity score matched comparison
Rob H.A. Verhoeven, Steven C. Kuijper, Florian Lordick, Marije Slingerland, Ailing Qin, Hanneke W.M. van Laarhoven
1citations -
1976P Financial difficulties experienced by gastrointestinal stromal tumor (GIST) patients in the Netherlands: Data from a cross-sectional multicenter study2023 Annals of Oncology article Economics, Econometrics and Finance Economic and Financial Impacts of Cancer Open access
Deborah van de Wal, Dide den Hollander, Ingrid M.E. Desar, Hans A. J. Gelderblom, Astrid W. Oosten, A.K.L. Reyners, +3 more
1citations -
1919P Nintedanib (BIBF1120) after first line therapy in progressive medullary thyroid cancer: A multicenter EORTC prospective randomized double-blind phase II study (NCT01788982)
Katie L. Newbold, Patrick Schoeffski, Baktiar Hasan, Laura D. Locati, Yann Godbert, Christelle de la Fouchardière, +10 more
1citations -
1130P BRAF and MEK inhibition in CDKN2A germline carriers and BRAF mutant melanoma2020 Annals of Oncology article Biochemistry, Genetics and Molecular Biology Melanoma and MAPK Pathways Open access
Francesco Spagnolo, Bruna Dalmasso, Hildur Helgadóttir, Veronica Höiom, Remco van Doorn, Ellen Kapiteijn, +4 more
1citations -
1622MO Clinical benefit with ripretinib as ≥4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST): Update from the phase III INVICTUS study
John Raymond Zalcberg, Michael Charles Heinrich, Suzanne George, Sebastian Bauer, Hans A. J. Gelderblom, Patrick Schöffski, +12 more
1citations -
37P First-line BRAF/MEK-inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: A propensity-matched survival analysis2020 Annals of Oncology article Biochemistry, Genetics and Molecular Biology Melanoma and MAPK Pathways Open access
Jesper van Breeschoten, Michel W.J.M. Wouters, Doranne L. Hilarius, J.B.A.G. Haanen, C.U. Blank, MJB Aarts, +13 more
1citations -
1018P Characterization of liver function tests following tebentafusp in phase III randomized trial comparing tebentafusp with investigator’s choice in first line metastatic uveal melanoma (mUM)
Bartosz Chmielowski, Ellen Kapiteijn, Paolo A. Ascierto, Friedegund Elke Meier, Shaad Essa Abdullah, Patricia Méndez, +1 more
1citations -
9P Long term recurrence risk predictions by CanAssist breast in a sub-cohort of TEAM trial2022 Annals of Oncology article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
M. Bakre, Arpitha Gunda, Elma Meershoek‐Klein Kranenbarg, B.A. Savitha, C. Prakash, P. Shrivastava, +6 more
1citations -
70P Fluoropyrimidine (FP) dose individualization based on pretreatment uracil levels: Safety and pharmacokinetic (PK) analysis from the Alpe2U study2022 Annals of Oncology article Pharmacology, Toxicology and Pharmaceutics Pharmacogenetics and Drug Metabolism Open access
Mirjam de With, Jonathan Emanuel Knikman, A. Baars, G-J.M. Creemers, H.J. Droogendijk, Edward Fiets, +14 more
1citations